CDA | Evidence Driven
CDA | Evidence Driven

Opdivo in combo with Yervoy for Renal Cell Carcinoma – Details

Details

Files
Generic Name:
Nivolumab in combination with Ipilimumab
Project Status:
Complete
Therapeutic Area:
Advanced or Metastatic Renal Cell Carcinoma (RCC).
Manufacturer:
Bristol-Myers Squibb
Brand Name:
Opdivo in combination with Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0132-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
10 mg/mL
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma
Funding Request:
Intermediate/poor risk patients with previously untreated, advanced or metastatic renal cell carcinoma (RCC)
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - pERC Final Recommendation Final Recommendation November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - Final Clinical Guidance Report Guidance Reports November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - Final Economic Guidance Report Guidance Reports November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - pERC Initial Recommendation Initial Recommendation August 30, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - PAG Feedback on pERC Initial Recommendation Feedback November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - Submitter Feedback on pERC Initial Recommendation Feedback November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - Clinician Feedback on pERC Initial Recommendation Feedback November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - Patient COI Declarations COI Declarations November 1, 2018 View PDF
Nivolumab (Opdivo) Ipilimumab (Yervoy) RCC - Clinician COI Declarations COI Declarations November 1, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 16, 2018